VistaGen Therapeutics披露的最新数据显示,其药物在安全性及耐受性方面的表现令人鼓舞,这一结果与先前开展的临床试验所得结论高度吻合。该积极数据进一步巩固了公司研发管线的可靠性,为后续的临床开发路径提供了有力支持。
VistaGen Therapeutics披露的最新数据显示,其药物在安全性及耐受性方面的表现令人鼓舞,这一结果与先前开展的临床试验所得结论高度吻合。该积极数据进一步巩固了公司研发管线的可靠性,为后续的临床开发路径提供了有力支持。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.